低发病率地区癌前胃病变的监测:一项多中心前瞻性队列研究
该多中心前瞻性队列研究纳入荷兰和挪威既往诊断为萎缩性胃炎、肠上皮化生或异型增生的279例患者,提供内镜监测并随访平均57个月。随访期间4例(1.4%)进展为高级别腺瘤/异型增生或浸润性肿瘤,总体肿瘤进展风险为每年0.3%;与广泛AG/IM患者相比,局限AG/IM患者未发生进展(p=0.02)。作者认为在低胃癌发病率地区监测项目可早期可治愈阶段检出胃癌,血清学标志物可能改善风险分层。
要点
- 279例癌前胃病变患者随访平均57个月,4例(1.4%)进展为高级别腺瘤/异型增生或浸润性肿瘤,年进展风险0.3%。
- 局限AG/IM(PG I/II>3且OLGIM 0-II期)患者随访期间未发生高级别腺瘤/异型增生或浸润性肿瘤,与广泛AG/IM患者相比差异有统计学意义(p=0.02)。
- 作者认为在低胃癌发病率地区监测项目可早期可治愈阶段检出胃癌,血清学标志物可能改善风险分层。
核心结论
- 在低胃癌发病率地区,监测项目可在早期可治愈阶段检出胃癌,总体肿瘤进展风险为每年0.3%。
- 在内镜监测项目中使用血清学标志物可能改善风险分层。
研究设计与样本
- 多中心前瞻性队列研究,纳入荷兰和挪威既往诊断为萎缩性胃炎(AG)、肠上皮化生(IM)或异型增生的患者,提供内镜监测。
- 所有组织学标本按更新悉尼分类和可操作的胃肠上皮化生评估(OLGIM)系统评估,并检测血清胃蛋白酶原(PG)和胃泌素-17。
- 共纳入279例患者(平均年龄57.9岁,标准差11.4,男/女137/142),随访期间至少接受一次监测内镜,平均随访时间57个月(标准差36)。
主要发现
- 随访期间4例(1.4%)诊断为高级别腺瘤/异型增生或浸润性肿瘤(即胃癌)。
- 上述4例中2例成功接受内镜黏膜下剥离术,另2例接受全胃切除术。
- 与广泛AG/IM患者(PGI/II≤3和/或OLGIM III-IV期)相比,局限AG/IM患者(PG I/II>3且OLGIM 0-II期)随访期间未发生高级别腺瘤/异型增生或浸润性肿瘤(p=0.02)。
临床怎么用
- 作者认为在低胃癌发病率地区监测项目可早期可治愈阶段检出胃癌。
- 作者认为在内镜监测项目中使用血清学标志物可能改善风险分层。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: International guidelines recommend endoscopic surveillance of premalignant gastric lesions. However, the diagnostic yield and preventive effect require further study. We therefore aimed to assess the incidence of neoplastic progression and to assess the ability of various tests to identify patients most at risk for progression. DESIGN: Patients from the Netherlands and Norway with a previous diagnosis of atrophic gastritis (AG), intestinal metaplasia (IM) or dysplasia were offered endoscopic surveillance. All histological specimens were assessed according to the updated Sydney classification and the operative link on gastric intestinal metaplasia (OLGIM) system. In addition, we measured serum pepsinogens (PG) and gastrin-17. RESULTS: 279 (mean age 57.9 years, SD 11.4, male/female 137/142) patients were included and underwent at least one surveillance endoscopy during follow-up. The mean follow-up time was 57 months (SD 36). Four subjects (1.4%) were diagnosed with high-grade adenoma/dysplasia or invasive neoplasia (ie, gastric cancer) during follow-up. Two of these patients were successfully treated with endoscopic submucosal dissection, while the other two underwent a total gastrectomy. Compared with patients with extended AG/IM (PGI/II≤3 and/or OGLIM stage III-IV), patients with limited AG/IM (PG I/II>3 and OLGIM stage 0-II) did not develop high-grade adenoma/dysplasia or invasive neoplasia during follow-up (p=0.02). CONCLUSION: In a low gastric cancer incidence area, a surveillance programme can detect gastric cancer at an early curable stage with an overall risk of neoplastic progression of 0.3% per year. Use of serological markers in endoscopic surveillance programmes may improve risk stratification.
引用
- den Hollander WJ, Holster IL, den Hoed CM, et al. Surveillance of premalignant gastric lesions: a multicentre prospective cohort study from low incidence regions. Gut. 2018. PMID: 29875257. doi:10.1136/gutjnl-2017-314498
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。